Comprehensive medication guide to Myfortic including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$10–$75 copay; generic usually Tier 2–3, prior authorization commonly required, step therapy through CellCept may apply.
Estimated Cash Pricing
$500–$900 retail for a 30-day supply; as low as $43–$100 for the generic with GoodRx or SingleCare coupons.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Myfortic is the brand name for mycophenolic acid (as mycophenolate sodium) in a delayed-release tablet formulation. It belongs to the class of selective immunosuppressants known as IMPDH inhibitors. Myfortic is FDA-approved for the prevention of organ rejection in adult patients who have received kidney transplants, and in pediatric patients aged 5 and older who are at least 6 months post kidney transplant. It is always used in combination with cyclosporine and corticosteroids.
Myfortic is also used off-label for conditions such as lupus nephritis, systemic lupus erythematosus (SLE), vasculitis, myasthenia gravis, autoimmune hepatitis, and certain autoimmune skin conditions like pemphigus.
![Why Is Myfortic So Hard to Find? [Explained for 2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F6b11a47f3ad97b28b1f25da609c6e552ad54fee0-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
![How to Find a Doctor Who Can Prescribe Myfortic Near You [2026 Guide]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2Ff50344b9ba827d824c5951872c9abf2dcc666907-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Myfortic contains mycophenolic acid (MPA), which works by inhibiting inosine monophosphate dehydrogenase (IMPDH), an enzyme critical for the production of guanosine nucleotides. T-cells and B-cells — the immune cells responsible for organ rejection — depend heavily on this pathway to multiply. By blocking IMPDH, Myfortic selectively suppresses the proliferation of these lymphocytes, reducing the immune response that would otherwise attack a transplanted kidney.
The delayed-release (enteric-coated) formulation is designed to release the medication in the small intestine rather than the stomach, which may help reduce some of the gastrointestinal side effects associated with mycophenolate products.
180 mg delayed-release tablets
360 mg delayed-release tablets
Myfortic (Mycophenolic Acid delayed-release) scores a 55 out of 100 on our findability scale, indicating intermittent availability issues. Brand-name Myfortic from Novartis has generally remained in stock, but generic mycophenolate sodium delayed-release tablets have experienced supply disruptions from multiple manufacturers. Patients relying on the generic may need to call several pharmacies or check availability through Medfinder to locate it in stock near them.
If you're having trouble finding Myfortic or its generic equivalent, ask your transplant team about switching between brand and generic options, or consider checking specialty pharmacies that serve transplant patients.
Myfortic carries a boxed warning stating that only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe it. Specialists who commonly prescribe Myfortic include:
No. Myfortic is not a controlled substance and has no DEA schedule. It does not carry a risk of abuse or dependence. However, it is a high-risk medication that requires close medical supervision due to its immunosuppressive effects, boxed warnings for malignancy and serious infections, and the risk of embryofetal toxicity. Prescriptions are typically managed through transplant centers or specialty pharmacies.
Serious side effects include increased risk of lymphomas and skin cancers, serious or fatal infections (including progressive multifocal leukoencephalopathy), polyomavirus-associated nephropathy, GI bleeding or perforation, and embryofetal toxicity. Report any unusual symptoms to your transplant team immediately.
Know what you need? Skip the search.
CellCept (Mycophenolate Mofetil)
A prodrug of mycophenolic acid with the same mechanism. Available as capsules, tablets, oral suspension, and IV. More widely available and often less expensive, though it may cause more GI side effects than enteric-coated Myfortic.
Azathioprine (Imuran)
An older immunosuppressant that inhibits purine synthesis. Less potent than mycophenolate products but has a well-established safety profile. Used for transplant rejection and various autoimmune conditions.
Everolimus (Zortress)
An mTOR inhibitor with a different mechanism of action. Used in combination with reduced-dose calcineurin inhibitors for kidney transplant patients.
Belatacept (Nulojix)
A selective T-cell costimulation blocker given as an IV infusion. An option for patients who cannot tolerate calcineurin inhibitors or mycophenolate products.
Prefer Myfortic? We can find it.
Azathioprine
moderateDo not use together; both suppress purine metabolism, greatly increasing bone marrow suppression risk.
Live vaccines
moderateAvoid during Myfortic therapy, as they may be ineffective and could cause infection in immunosuppressed patients.
Cholestyramine and bile acid sequestrants
moderateSignificantly reduce mycophenolic acid levels; avoid concomitant use.
Acyclovir, Valacyclovir, Ganciclovir, Valganciclovir
moderateCompete for kidney excretion; levels of both drugs may increase, especially with impaired kidney function.
Rifampin
moderateCan reduce mycophenolic acid levels through enzyme induction.
Antacids (magnesium/aluminum)
moderateReduce absorption; space doses apart.
Proton pump inhibitors (PPIs)
moderateMay reduce mycophenolic acid exposure.
Hormonal contraceptives
moderateMyfortic may reduce oral contraceptive effectiveness; use additional barrier methods.
Myfortic is a critical immunosuppressant for kidney transplant recipients, and maintaining an uninterrupted supply is essential to preventing organ rejection. While the brand-name product from Novartis has generally remained available, generic mycophenolate sodium delayed-release tablets have experienced intermittent supply disruptions that can cause significant stress for patients.
If you're having difficulty finding Myfortic or its generic in stock, use Medfinder to search pharmacies near you. Specialty pharmacies affiliated with transplant centers may have more reliable stock. You can also explore manufacturer savings through Novartis SaveOnMyPrescription or patient assistance through the Novartis Patient Assistance Foundation if cost is a barrier.
Never skip doses or modify your immunosuppression regimen without guidance from your transplant team — the consequences of rejection far outweigh the inconvenience of finding your medication.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini